公司資料
bluebird bio, Inc. 股價、新聞與催化劑
- 股票代碼:
- BLUE
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for BLUE.
公司概覽
業務概覽
bluebird bio was a gene-therapy company focused on severe genetic disease and oncology before its restructuring and exit from the public market. Its legacy was built around one of the earliest commercial gene-therapy platforms.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ before restructuring, bluebird sat in gene therapy.
商業模式特徵
The business depended on clinical progress, manufacturing, and commercialization of gene-based medicines.
生技產業定位
bluebird bio was a landmark gene-therapy company and is now best treated as a legacy platform case.
未來催化劑
- bluebird bio is now mostly a closeout and legacy-asset story, so the next catalysts are any remaining commercial, regulatory, or transaction milestones tied to its gene-therapy portfolio. Investors will watch for clarity on what value, if any, remains after the strategic unwind.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。